Thus, expression of SPX as a ligand and its receptors GALR2/3 in the GC, as well as the described role of adipokines in PCOS, suggests that SPX may also be an interesting player in GC physiology and future target for treatment intervention. This evidence concerns the gene GALR2 and polycystic ovary syndrome.